Forty-nine patients with decreased fibrinolytic activity in the vessel walls or a decreased release mechanism, or both, were treated with ethyloestrenol for three to 17 months. Forty-five of the patients had had recurrent, phlebographically verified, deep venous thrombosis (DVT) and four had arterial thrombosis. Ethyloestrenol 8 mg/day was given to 31 patients and 4 mg/day was given to 12. The ...

Research on new fibrinolytic agents has been oriented towards the discovery of microbial proteases with plasmin-like activity, as alternative thrombolytic for thrombosis treatment. This study reports characterization an extracellular serine metalloprotease approximately 56 kDa, and fibrinogenolytic isolated from a S. marcescens strain obtained Amazon (CBAM 519). The enzyme showed optimum activi...

Hypercoagulability is a state in which the hemostatic balance shifts toward excessive platelet activation and fibrin deposition, leading to thrombosis. Although a definitive diagnosis is often difficult to make, identifying patients at risk for thromboembolism is critical. By identifying these patients and understanding mechanisms that contribute to hypercoagulability, clinicians can select pro...

Cardiovascular disease (CVD) is the leading cause of death in developed and many developing countries. Between 1970 and 1992 there has been a slow decline in some areas, notably North America, Western Europe, Australia, and New Zealand. However, CVD mortality has recently increased in Eastern and Central Europe. A whole spectrum of therapeutic tools is available to manage CVD including thrombol...

OBJECT The goal of this study was to determine the risk of using antithrombotic agents in patients with established intracerebral cavernous malformations (ICMs). METHODS From a previously described cohort of 292 patients with radiographically defined ICMs, 40 required an antithrombotic after the ICM was diagnosed. Patients underwent follow-up to determine the incidence of hemorrhage. RESULT...

Thromboembolic events are an increasingly common secondary complication in children who are successfully treated for serious, life-threatening primary diseases. In contrast to adults, thromboembolic events are rare enough in children to hinder clinical trials assessing optimal use of antithrombotic agents. Currently, pediatric patients are treated according to guidelines extrapolated from adult...

OBJECTIVE To determine the effect of diabetes on long-term survival after acute myocardial infarction and to compare its effect with that of a previous myocardial infarction. RESEARCH DESIGN AND METHODS In a prospective cohort study, we followed 1,935 patients hospitalized with a confirmed acute myocardial infarction at 45 U.S. medical centers between 1989 and 1993, as part of the Determinant...

Anticoagulation is the cornerstone of therapy in patients with ischemic cardiovascular disease. In patients who develop an acute coronary syndrome, following percutaneous coronary interventions, or with an acute ischemic stroke, the rupture or injury of an atherosclerotic arterial plaque serves as a nidus for platelet aggregation and thrombus formation, which, in turn, may cause myocardial infa...

The resting blood fibrinolytic activity of 120 normal subjects and 294 patients with various forms of vascular disease was assessed by measuring the dilute blood clot lysis time and fibrin plate lysis area before and after 10 minutes of venous congestion. The tissue fibrinolytic activity of several of these subjects was assessed in vein biopsy specimens. The results suggested that there was a c...